The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Evolution of Nanocarrier Drug-Delivery Systems and Recent Advancements in Covalent Organic Framework–Drug Systems
Abstract
Nanotechnology has been actively employed in the development of drug-delivery systems overcoming the limitations of conventional carriers. In nanomedicine, the ultimate goal is to design and develop a system for the prevention, diagnosis, control, and treatment of debilitating diseases. Nanoparticles can be designed and programmed to have unique physical properties, in order to protect the loaded drug against degradation and/or denaturation by natural processes inside the body, while selectively delivering it to target areas having the desired cells. This effectively minimizes the active pharmaceutical ingredient’s (API’s) systemic exposure and, consequently, the occurrence of adverse side effects. The enhanced control on the distribution and release of the entrapped drug molecules, through active targeting and controlled-release technology, allows for their increased and accurate cellular uptake. In this review, we summarize the development of nanobased drug-delivery systems, with a focus on smart systems and the necessary characteristics required for the optimal drug nanocarrier. The recently developed class of crystalline porous polymers, covalent organic frameworks (COFs), possesses a unique combination of characteristics including permanent yet tunable discrete pores having high surface areas and large volumes, making them intrinsically designed to accommodate APIs as guest molecules in their highly ordered pores. The extensive synthetic and molecular design flexibility of COFs allows the structural control and tuning of their morphology, regularity, atomic connectivity, and porosity, for this specific application. Through an overview of the recent advancements in the novel application of metal–organic frameworks (MOFs) and COFs as drug nanocarriers, we demonstrate this promising alternative route to effectively increase the drug solubility and enhance the limited loading capacity and release control of nanoparticle systems. Since the first reported COF nanocarriers in 2011 as passive targeting drug-delivery systems, this application of COFs has been slowly gaining traction, with increasingly complex COF nanocarrier drug-delivery systems reported in the past year.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Mahapatro, A., & Singh, D. K. (2011) · Journal of Nanobiotechnology · doi:10.1186/1477-3155-9-55 · Cited by 685
Biocompatibility and drug delivery systems
Kohane, D. S., & Langer, R. (2010) · Chem. Sci. · doi:10.1039/c0sc00203h · Cited by 307
Liu, S. Q., Tong, Y. W., & Yang, Y. Y. (2005) · Molecular BioSystems · doi:10.1039/b501756b · Cited by 74
Cited by
Emerging 2D nanomaterials for biomedical applications
Murali, A., Lokhande, G., Deo, K. A., Brokesh, A., & Gaharwar, A. K. (2021) · Materials Today · doi:10.1016/j.mattod.2021.04.020 · Cited by 349
Metadata
- Authors
- Scicluna, M. C., & Vella-Zarb, L.
- Venue
- ACS Applied Nano Materials
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-03-12
- Volume
- 3
- Issue
- 4
- Pages
- 3097-3115
- ISSN
- 2574-0970 (ISSN-L)
- OpenAlex
- W3012481191
- Cited by
- 211
- References
- 4
- FWCI
- 6.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.